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Summary 
Natural Killer (NK)I.1 +  (NK1) T  cells are a specialized subset of ti/[3 T  cells that coexpress 
surface receptors that are normally associated with the NK cell lineage of the innate immune 
system. On recognition of the conserved, major histocompatibility complex class I-like CD1 
molecule, these cells are able to release explosive bursts of interleukin 4 (IL-4), a cytokine that 
promotes the T  helper type 2 (Th2) effector class of an immune response. A unique feature of 
their T  cell receptor (TCIL) repertoire is the expression of an invariant TCR ot chain, Vcl14- 
Jix281, and of a restricted but polyclonal set of V[3 gene families,  V[38, V~7, and V[32. Here, 
we show that transgenic expression of this TCR ot chain during thymic development is suffi- 
cient information to bias the differentiation of mainstream thymocytes towards the NK1 devel- 
opmental pathway. It markedly increases the frequency of cells with the NK1 pattern of T  cell 
differentiation and also has drastic consequences for the selection of the V[3 repertoire. Trans- 
genic CD4 cells exhibited a 10-100-fold increase in IL-4 production on mitogen stimulation 
in vitro and in vivo, and baseline levels of the Th2-controUed serum immunoglobulin isotypes, 
IgE and IgG1, were also selectively elevated in vivo. 
U 
'nlike mainstream el/13 T  cells,  NK1  T  cells acquire, 
during thymic development, the unusual property of 
secreting IL-4  on  primary stimulation,  and  of expressing 
receptors normally associated with the NK lineage such as 
NKI.1  (reviewed in references 1-3).  Their positively se- 
lecting ligand appears to be the conserved MHC class I-like 
molecule  CDI,  expressed  on  cortical  thymocytes  (4,  5) 
rather than the polymorphic MHC restriction elements ex- 
pressed  on  thymic  epithelium  (6-9),  and  their  resulting 
TCP,.  repertoire  is  severely  limited.  More  than  85%  of 
NK1  T  cells  express  an  invariant  TCR  ot  chain,  VoH4- 
Jot281  (10),  and a limited set  of TCIL V[3  chains  (V~8,7 
and 2)  (8,  11-15) which, together, generate specificity for 
CD1  in  the  apparent  absence  of foreign antigens  (4,  5). 
NK1  T  cells are found among mature HSN  ~  thymocytes 
as  single  positive  CD4+8 -  (the main  IL-4 producer) and 
double-negative  (DN) 1 CD4-8-  cells,  but  they  are  re- 
markably absent from the CD8+4 -  subset (8, 10). Humans 
have a similar set of T  cells that use the invariant TCR ot 
1Abbreviations used in this paper: DN, double negative; EAE, experimental 
allergic encephalomyelitis. 
chain Vc124-JotQ,  and  V[311,  the  homolognes  to  mouse 
Vct14-J0t281  and V[38, and humans also express a homolo- 
gous CD1  ligand, the CDld molecule (10,  16,  17).  Thus, 
NK1  T  cells seem to belong to an ancient cell type, strad- 
dling the innate and adaptive immune systems, whose semi- 
invariant  ci/[3  TCRs  and  conserved CD1  ligand  predate 
the speciation of mouse and man. 
Their  high  frequency  in  peripheral  lymphoid  tissues 
(0.5-1% of spleen and LN cells), and their ability to explo- 
sively release IL-4 in response to CD1  induction on APC 
might strongly shift the effector class of immune responses 
towards Th2 (4,  18,  19).  Indeed, NK1  T  cells are essential 
for generating the polyclonal Th2 and IgE response that is 
induced  upon  intravenous  injection  of goat  anti-mouse 
IgD antibodies (20). This can have profound consequences 
on subsequent immunizations. For example, preimmuniza- 
tion with myelin basic  protein coupled to mouse anti-rat 
IgD  antibody induced myelin basic  protein~pecific Th2 
cells and protected rats from subsequent attempts to induce 
experimental allergic encephalomyelitis (EAE)  (21).  In ad- 
dition, NK1  T  cells are severely deficient in SJL (22)  and 
nonobese diabetic  (23)  mice, two strains  which  are con- 
spicuously susceptible to  Thl-mediated  autoimmune  dis- 
eases, EAE and diabetes, respectively. This raises the possibil- 
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deviate tissue-destructive Thl  responses. 
Since CD1  is constitutively expressed by cortical double- 
positive CD4+8 + thymocytes, the cell type that appears to 
positively select the NK1  T  ceils (5), it is available for rec- 
ognition  by  developing thymocytes  that  express  a  CD1- 
specific TCR..  We therefore used a transgenic approach to 
investigate  the  consequences  of  expression  of  a  Vet14- 
Jet281 +  TCR  on  thymocyte  development.  We  generated 
transgenic mice expressing the rearranged Vet14-Jet281 trans- 
gene  under  the  control  of an  endogenous  Vet  promoter, 
the Vet11 promoter, and the Ig enhancer (24). The TCR  et 
chain transgene was tested alone, without a TCR  [3 chain 
transgene,  to determine the extent to which it determines 
the  NK1  developmental  fate  of mainstream  thymocytes. 
Our results indicate that expression of the canonical Vet14- 
Jet281 + TCIZ et  chain has drastic consequences on the se- 
lection of TCR.  [3 chains of the V[38  and V[~7  families as 
well  as  on  the  NK1  differentiation  and  function  of thy- 
mocytes. In addition, transgenic mice exhibited a major in- 
crease in their potential to produce IL-4, as well as in their 
baseline levels of Th2-controlled isotypes, in particular IgE. 
Materials  and Methods 
Transgenic and Mutant Mice.  Vot14-Jot281 and Vot8-Jot37 gene 
segments were PCP.-amplified from genomic DNA of the CD1 
specific T  cell hybridoma DN32D3  (10)  and the IAa/rabbit Ig- 
specific T  cell clone CDC35, respectively (25), and cloned into a 
TCR  ci  shuttle  vector containing the  Vodl  endogenous  pro- 
moter  and  the  Ig enhancer  as  described  (24).  Linearized con- 
structs  were  injected  into  B6  fertilized  eggs,  and  transgenic 
founders screened by tail DNA PCR with specific primers. 
C57BL/6,  and  C57BL/6.Ctx  null  mice  (TCR  ot  knockout 
[26],  backcrossed nine  times to  B6)  were purchased from  The 
Jackson  Laboratory (Bar  Harbor,  ME)  or Taconic  Farms,  Inc. 
(Germantown, NY) and raised under specific pathogen-free con- 
ditions. Voe14-Jot281 transgenic mice with a homozygous nmta- 
tion  of the  endogenous  Cot  genes  were  generated  by crossing 
transgenics to Cot mutants, selecting for offsprings  that expressed 
oe/13 TCR high blood cells  without  using  endogenous  Vot  gene 
products (detected using a combination of anti- Vo~2, Vc~8 and 
Vctl I antibodies). 
FACS  ~  Analysis~Sorting.  Thymocyte and spleen cell suspen- 
sions were three- or four-color stained using combinations of an- 
tibodies conjugated to  tricolor (anti-CD4;  Caltag Laboratories, 
South San Francisco, CA), red 613 (anti-CDS; GIBCO BKL Life 
Technologies, Gaithersburg, MD),  FITC, and PE (or biotin fol- 
lowed by PE-conjugated streptavidin [Caltag]), and analyzed us- 
ing a modified FACScan  |  (Becton Dickinson and Co., Mountain 
View, CA). FITC-conjugated anti-pan-TCRJ3 (H57), anti-CD3~ 
(500.A2), or anti-CD8 (53.6.7), biotin-conjugated anti-pan-TCR[3 
(H57),  VJ37 (TR310), V[36 (RR4.7), VJ310 (B21.5), V[314 (14-2), 
Vet2  (B20.1),  Vot11 (RR8-1),  Vet8  (B21.14),  PE-conjugated 
anti-NKl.1  (PK136)  and  CD5  (53-7.3),  and  APC-conjugated 
anti-CD8 (53.6.7)  were purchased from PharMingen (San Diego, 
CA). Biotinylated F23.1  anti-Vj38 was produced in the labora- 
tory.  FACS  |  sorting  was  performed  using  a  Vantage  (Becton 
Dickinson and Co.) equipped with dual (argon and dye) lasers. 
Cell Preparations and Cytokine Production Assays.  T  cell-enriched 
spleen cells were obtained after MACS (Miltenyi Biotec, Bergish 
Gladbach,  Germany)  depletion  of Y3P  anti-IA  h  positive  cells 
(>90% TCP. or/13+). T  cell subsets  were purified (>98% pure) 
from T cell-enriched preparations by FACS  |  sorting after staining 
with anti-CD4-FITC, anti-CD8-APC, and CD5-PE. 4  ￿  105 en- 
riched T  cells or 10  s subsetted cells were stimulated in vitro with 
anti-CD3  antibody  (2Cll,  1  I.~g/ml)  in  the  presence  of  10  s 
2,000-rad irradiated, T  cell-depleted spleen cells (pretreated with 
anti-CD4 (RL172.4), anti-CD8 (3.155),  and anti-Thyl (J 1J) anti- 
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ries Ltd., Hornby, Canada) for 45 mn at 37~  in a final volume 
of a 1:1 mixture of RPMI and Click's media enriched with 10% 
heat inactivated FCS, 5  ￿  10 -5 M  2-ME, penicillin, streptomy- 
cin,  and gentamycin (complete medium),  in a  96-U-bottomed 
well microplate. Cytokines released in the supernatant were mea- 
sured 48 h later using the IL-4-sensitive CT4.S line and the IFN-'y 
sandwich ELISA as described (27). 
For in vivo stimulation with anti-CD3, mice were injected i.v. 
with 1 ~g 2Cll anti-CD3 antibody, and spleen cells removed 90 
rain later and cultured, without further stimulation, as described 
(18), at a density of 10  v cells in 2 ml of complete medium for 2 h 
to measure cytokine release in the culture supematant. 
Serum Ig Isotype Levels.  Serum levels oflg isotypes were mea- 
sured by standard sandwich ELISA (IgA, M, G1, G2a, G2b, G3; 
Southern  Biotechnology, Birmingham,  AL;  IgE;  PharMingen). 
The average level of each isotype in normal mice was set up arbi- 
trarily at 100 U/ml. 
Results 
Altered T  Cell Development and  V~8 Usage in  Vee14-Joe281 
Transgenic Mice.  Four  distinct  founder  lines  of mice  ex- 
pressing  the  Vcl14-Joe281  transgene  were  produced  in  a 
C57BL/6  background,  as well as a  control line expressing 
Vot8-Jot37,  a  TCR  ot  chain  not  associated with  NK1  T 
cells  (25).  Because  there  exists  no  antibody  specific  for 
Veil4, surface expression of the Vod4-Jot281  ct chain was 
confirmed by showing that transgene expression rescued T 
cell development in TC1< C(x null mice (Fig. 1, third col- 
umn). Transgene expression was also evident from the phe- 
notype described below. 
A  common  feature  of all four  V(x14-Jcx281  transgene- 
expressing lines was a fivefold reduction in thymus size, af- 
fecting  mainly  double-positive  thymocytes  (Fig.  1).  This 
size reduction did not occur in mice expressing the control 
Vot8-Jot37  transgene,  suggesting that  a  bypass of the  dou- 
ble-positive stage of thymic development (28, 29)  or a de- 
letion at  that  stage  had  occurred  as a  consequence  of the 
Vcx14-Jot281  TCI<  specificity.  A  30%  reduction  of  the 
number ofT  cells was also observed in the spleen of Vcil4- 
Jot281  transgenics together with  a  marked increase in DN 
(x/~ T  cells (Fig. 1). 
In normal mice, both the CD4 and the DN NK1  T  cells 
use mainly Vl38,  Vl37,  and Vl32 TCI<  13 chains. We have 
suggested that,  coupled with Vod4-Jot281,  these  13  chains 
allow for  high  affinity CD1  binding.  Indeed,  this  affinity 
seems to be high enough  that the additional binding con- 
tributed  by  the  CD8  coreceptor  induces  deletion.  Thus, 
normal mice do not have CD8 cells expressing these TCP,  s 
and the forced, transgenic expression of CD8 induces dele- 
tion of the entire Vod4-J0r  + NK1  T  cell subset (8,  10). 
Figs. 2  and 3  show that the CD8  single-positive compart- 
ment  in  transgenic  mice  was  selectively depleted of cells 
expressing the  V[38  and  V137 TCR.  13  chains  most  com- 
monly  used  by  NK1  T  cells whereas  control  V[36 +  cells 
were not deleted (Figs. 2 and 3). The extent of this deletion 
indicated therefore that a majority of Vl38 and Vl37 TCR. 
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Figure 2.  TCR ot and 13 repertoire in Vot14-J~t281 transgenic mice. 
Thymocytes from 6-wk-old mice of each of the four Vot14-J(x281 trans- 
genic founder lines (913, 899, 901, 921), from the Vod4-Jot281 trans- 
genic 921  line in a Ctl-null background, from littemmte controls, and 
from Vcx8-Jet37 transgenics were three-color stained with CD4 tricolor, 
CD8-FITC, and biotinylated anti-VI38, VJ37, V[36, Vot2, and pan-TCR[B 
followed by streptavidin PE. Percentages of VIB and Vot expressing ma- 
ture CD4 and CD8 ceils are obtained after normalizing to the number of 
pan-TCRJ3-positive cells. Mean +- SD of three to six individual mice per 
group are represented. Similar results were obtained with spleen cells. 
13  chains  allow  for  CD1  recognition  when  paired  with 
Vod 4-Jet281. 
v[3 usage in the CD4  compartment was variable in dif- 
ferent lines oftransgenics. The frequency ofV137 + cells was 
increased three- to fourfold in lines 899,  921,  and 901, and 
unchanged in line 913, whereas V[38 + cells were increased 
by 50%  in line 901,  unchanged in lines 899  and 921,  and 
decreased by 50% in line 913  (Figs. 2 and 3). Such variabil- 
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Figure 3.  Downmodulation ofVI38 + and V[37  + TCRs on Vod4-Jc~281 transgenic CD4 + T cells. The 913 and 901 founder lines illustrated here dis- 
play a selective downmodulation ofV[38 + and Vl37  + TCRs on CI)4+8  - thymocytes, which is slightly more pronounced in the deleting 9t3 line. VI36  + 
C1)4+8  thymocytes display normal levels of surface TCP, expression. Note that CD8+4  -  thymocytes of both transgenic lines are severely depleted of 
V[38  + and V[37  + cells. 
ity in frequencies of V[38 + and VI37 + CD4  cells is likely to 
correlate with subtle changes in the level or the kinetics of 
expression of the transgene due to different sites of integra- 
tion in different lines, resulting in increased positive selec- 
tion  of CD4  ceils  using VI38  or  VI37  in  some  cases  and 
negative  selection  in others.  In  addition,  surface  levels  of 
VI38 and V~7  TCR  13 chains were found to be selectively 
decreased  in transgenic CD4  cells,  from  two-  to  threefold 
in lines 899,  901,  and 921,  up to fivefold in the "deleting" 
913 line (Fig. 3). This result again mimics the phenotype of 
normal NK1  T  cells which express  two  to  three  times less 
surface TCRs  than mainstream T  cells, and supports the as- 
sumption  that  high  V[38 +  and V~37 +  expressors  were  de- 
leted  or  that  they  downmodulated  their  TCR  levels  and 
escaped negative selection. 
NKI  T  Cell Surface Phenotype.  Vod4-J0~281  transgenics 
also exhibited an increased frequency of T  cells expressing 
surface  markers  associated  with the  NK1  phenotype.  This 
was reflected in the net 7- to  10-fold increase in the abso- 
lute numbers of NKI.1 +  o~/[3 TCR +  cells observed in the 
spleen of vcl14-Jcx281  transgenics (Fig.  1).  NK1.1  was ex- 
pressed on  12-24% of CD4 spleen cells (as  well as on 30- 
60% of DN  cells [see below]), but not on CD8 cells (Fig. 4). 
High  levels  of CD44,  another  hallmark  of NK1  T  cells, 
were  also  found on transgenic CD4  cells  (Fig.  4)  and DN 
cells (Fig.  5).  Results similar to  those shown in Figs. 4  and 
5  for spleen cells were also observed in mature HSN"" thy- 
mocytes (data not shown). 
DN  cr/~8 Tcells.  A  prominent subset  of DN  CD4-8- 
o~/~  TCR-expressing cells was  present in  increased num- 
CD44 
NK1.1 
CD4  CD8 
CONTROL  V~14-Ja281  Tg  CONTROL V~14-Ja281  Tg 
L.JL  
Figure 4.  Increased expression ofactivation/NK re- 
ceptors  by  Vod4-Jo~281 transgenic  C1)4 +  T  cells. 
Staining with anti-CD44-PE or anti-NKl.l-PE is dis- 
played on gated CD4 and CD8 spleen cells from con- 
trol and transgenic mice. 
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Figure  5.  Two populations of DN ~x/~ T  ceils in C~x null, Vcd4- 
Jix281 transgenic spleens. T cell-enriched spleen cells (obtained after pan- 
ning out MHC II- and Ig-positive cells) were stained with anti-CD4 tri- 
color, CD8-red 613, CD44-FITC, and biotinylated anti-TCP, antibodies 
followed by streptavidin-PE, CD44/TCP.13 dot plots on gated DN cells 
are represented, The  relative (calculated) frequency of V~8, V[37 and 
V[36-expressing cells among CD44  I~  and CD44  high DN T  cells is dis- 
played on the right side of the dot plots, 
sult demonstrates  first that the bias in V[38 and V~7  usage 
among normal NK1  T  cells is not the result of a preferen- 
tial physical pairing of these TCR  [3 chains with the Vci14- 
Jix281  TCR.  ix  chain,  and  therefore  suggests  that  these 
TCR. 13 chains are selected because they contribute affinity 
to  the  CD1  ligand.  Second,  it  reenforces  the  hypothesis 
that  the  NK1-  DN  T  cells  observed  in  "conventional" 
TCP. transgenic mice result from the enforced (transgenic) 
early expression  of an ix/J3  TCR  in  a separate  lineage  that 
does not usually express it,  possibly a y/8 committed pre- 
cursor, which follows different rules of selection and differ- 
entiation  (30-32).  Interestingly,  a  population  of CD44  high 
IL21<[3 + NK1.1 + double-negative T  cells has recently been 
observed  in  an  anti-K  b ix/J3  TCP.  transgenic  system  (33). 
As  in  the  anti-CD1  system,  the  NK1  surface  phenotype 
was ascribed to a higher than usual affinity (CD8-indepen- 
dent)  of the  anti-K  b  transgenic  ix/13 TCP.  for its  thymic 
ligand  during  positive  selection.  Another  transgenic  line 
expressing an anti-K  b TCR. of lower affinity (CDS-depen- 
dent)  only produced NK1- DN T  cells. 
Endogenous  TCR  ix  Chain  Usage  by  Transgenic  T  Cells. 
Although we could not directly monitor the  frequency of 
cells  expressing the transgenic ix chain due to the lack of an 
anti-Vix14  antibody,  FACS  |  staining  for Vix2  (Fig.  2),  as 
well as Vix8 and Vix11  (not shown),  which altogether  are 
expressed  by "~20%  of normal  T  cells,  indicated  that  the 
transgenic mice contained 25% fewer CD4 T  cells express- 
Table  1.  Increased  IL-4 Production by  Vix14-Joe281  Transgenic 
CD4  T cells 
bers  in  the  thymus  and  periphery  of Vix14-Jix281  trans- 
genic mice (Fig.  1).  Although this might be expected from 
the  original  association  of Vix14-Jix281 +  TCIks  and  DN 
NK1 T  cells  (10), it has also been observed that most TCP. 
transgenic mice, irrespective of their TCR. specificity, gen- 
erate  a  sizable  population  of DN  T  cells  (30-32).  Indeed, 
our  control  Vix8  transgenics  also  harbored  a  higher  fre- 
quency  of DN  ix/[3  T  cells  (which  expressed  the  Vix8 
transgenic chain [not shown]), although this frequency was 
two  times  lower than in Vix14-Jix281  transgenics  (Fig.  1). 
Importantly however,  the majority of Vix8 transgenic  DN 
cells did not express  activation/NK  receptors  (Fig.  1),  nor 
did  they display a  biased  usage  of V[3  gene  products  (not 
shown), implying that these unique features are the conse- 
quence  of particular  TCI< specificities.  A  closer examina- 
tion  of the Vix14-Jix281  transgenic  DN  cells  revealed that 
they could in fact be separated into two distinct subpopula- 
tions  of approximately  equal  size,  according  to  their  ex- 
pression of activation/NK receptors (Fig. 5).  The CD44hig  h 
(NKI.1 high) had a  markedly biased  usage of V[38  and V[37 
TCR.  [3  chains whereas  the  CD44  l~  subset  did  not.  This 
could be observed in mice with a homozygous mutation of 
their TCR  Cix genes (Fig. 5),  indicating that expression of 
the Vix14-Jix281  TCI< ix chain can lead to both VI3-biased 
NK1 + and V[3-nonbiased NK1- DN phenotypes. This re- 
[L-4  IFN-',/ 
U/ml 
In vitro, spleen T  cells 
Control No. 1  87  20 
No. 2  69  18 
Transgenic No. 1  7,398  3 
No. 2  3,097  4 
In vitro, T cell subsets 
Transgenic CD4  1,886 
CD8  1 
DN  261 
In vivo, spleen cells 
Control No. 1  68  1 
No. 2  125  1 
Transgenic No. 1  1,537  2 
No. 2  935  3 
No. 3*  1,084  2 
Levels of cytokines released in vitro by cells stimulated in vivo or in 
vitro with anti-CD3.  Similar results were obtained with mice from all 
four transgenic lines. 
*TCR. Cot-null mouse. 
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Figure  6.  Increased  frequencies of Th2- 
controUed lg isotypes  in Vcx14-Jcx281 trans- 
genic mice. Serum levels of Ig isotypes were 
measured  by  standard  sandwich  ELISA  in 
3-5-too-old  Vet14-J~t281  transgenic  mice, 
and littermate  controls. Six to eight individ- 
ual nfice were examined for each of the four 
transgenic  lines and all data  were pooled, as 
there was no detectable  difference  between 
the different  lines. The average level of each 
isotype in normal mice is set up arbitrarily  at 
100  U/ml.  IgE  average  levels  in  Vot14- 
Jix281  transgenic  mice are  increased  sixfold 
above controls (P <0.001) and IgGI are in- 
creased twofold (P <0.01). 
ing endogenous ix chains than control mice. This suggested 
that at least 25% of CD4 T  cells expressed the transgenic 
ix chain on their surface.  Conversely, no reduction  of en- 
dogenous ix chain  expression was observed on CD8  cells, 
again supporting the view that  CD8  cells  expressing high 
surface levels of the transgenic V0t14-Jix281  ix chain were 
deleted and that the remaining CD8 cells were those which 
expressed an endogenous ix chain capable of outcompeting 
Vix14-Jix281  for pairing with  the  TCP,.  [3  chain.  Indeed, 
mice  expressing  the  Vod4-Jix281  transgene  in  a  Cix-null 
background  exhibited  a  marked  reduction  of CD8  cells 
(Fig.l),  whereas their CD4 cells  contained an even higher 
frequency of V[38 + and V[37 + TCP,  s (Fig. 2). 
Biased IL-4 Production by Transgenic T Cells.  To test whether 
transgenic  expression  of Vix14-Jix281  also  induced  an in- 
crease in the functional potential to produce IL-4, we mea- 
sured  the  levels  of cytokines  released  upon  TCR  cross- 
linking with anti-CD3 antibody. In vitro, transgenic T  cells 
secreted ~60 times more IL-4 and 4 times less IFN-y than 
transgene-negative littermates (Table  1)  or than Vo~8-Jix37 
transgenic controls (not shown). As in normal mice, the in- 
creased IL-4 secretion was mainly contributed by CD4 + T 
cells (Table 1). 
In vivo, we measured the rapid release oflL-4 that is ob- 
served within 1 h of TCR. engagement, a specific feature of 
NK1  T  cells  (18).  Table  1 shows that Vix14-Jix281  trans- 
genic  spleen  cells  release  >10-fold  more  early  IL-4 than 
controls. Identical results for the in vitro and in vivo exper- 
iments  were  obtained  in  all  four Vix14-Jix281  transgenic 
founder lines tested,  as well as in TCP-. Cix-null mice ex- 
pressing the Vcx14-Jix281  transgene. 
Increased Baseline Levels of Th2-controlted Ig lsotypes.  If  NK1 
T  cells  are effective regulators of Thl/Th2  differentiation 
in  normal  conditions,  one  would  expect  the  transgenic 
mice to express a specific increase of thebaseline levels of 
the serum Ig isotypes that are promoted by IL-4, induced as 
a  result  of ongoing  immune  responses  to  environmental 
antigens. As shown in Fig.  6, Vix14-Jo~281  transgenic mice 
of all founder lines had a selective and conspicuous increase 
of IgE (sixfold above controls on average) and IgG1  (two- 
fold above controls), the two Th2-controlled isotypes (19, 
34). The blood levels of other isotypes including IgM, IgA, 
IgG2a, IgG2b, and  IgG3 were unchanged.  Control Vo~8- 
Jix37 transgenics,  raised under the same specific pathogen- 
free conditions, did not exhibit changes in IgE or IgG1 lev- 
els (not shown). 
Discussion 
Our results indicate that expression by mainstream thy- 
mocytes  of the  NK1  T  cell  Vot14-Jot281  TCR  ix  chain 
alone has drastic consequences on the positive and negative 
selection of V[3 chains in CD4 and CD8 cells, respectively, 
mimicking the CDl-specific Tell  repertoire expressed on 
normal NK1  T  ceils.  The extent of the depletion of V[38- 
and V[37-positive CD8 cells indicate that Vix14-Jix281  can 
pair with  a very large proportion  of TCR.  [3  chains  using 
the V[38 and V[37 gene families (which are used by 30-50% 
of the T  cell population in most mouse strains),  to form a 
TCR with affinity for CD1, and that the overall avidity of 
interaction is increased by the CD8 coreceptor. The results 
imply that,  from a developmental (and  evolutionary)  per- 
spective,  one may consider  that  expression  of the  Vix14- 
Jix281 + TCI< ix chain alone is sufficient information to bias 
the differentiation of a thymocyte towards the NK1  path- 
way. It remains to be tested, however, whether expression 
of the Vix14-Jix281  TCR  ix chain itself is genetically pro- 
grammed in NK1 T  cells, or whether it occurs randomly. 
The reduced size of transgenic thymuses and the slightly 
1290  Transgenic Expression of Invariant Vix14-Jct281 TCR ix Chain different degrees of positive vs negative selection between 
transgenic founder lines are compatible with the view that 
Vcl14-Jot281 + TCIKs have an intrinsically high avidity for 
their  CD1  ligand  (8,  10,  35).  In addition,  the  transgenic 
system, by virtue of its earlier TC1K expression, may pro- 
ject an exaggerated picture of the normal selection process. 
Together with  a  recent  report  showing  that  a  transgenic 
TCIK unrelated  to  the  NK1  T  cell lineage  could also  in- 
duce the differentiation of DN NK1 T  cells,  provided that 
the avidity for its  thymic ligand was high  (33),  our results 
support the contention  that expression of receptors of the 
NK lineage and differentiation into DN T  cells can be im- 
parted to mainstream T  cell precursors during their thymic 
development. 
Support for the involvement of a distinct signaling path- 
way in the induction of the NK1 T  cell phenotype comes 
from recent  studies  by Aberola-Ila et al.  (36)  who  found 
that NK1 T  cells were normally generated in the face of an 
ablation of the 1kas/Raf/Mek/Map kinase pathway which 
mediates the  positive but  not negative selection  of main- 
stream thymocytes. The quality, or the avidity, of the inter- 
action  between  the  developing thymocyte and the  ligand- 
presenting  cell,  and  the  resulting  differences in  signaling, 
may  therefore  influence  the  functional  differentiation  of 
thymocytes, as previously suggested in  models  of positive 
selection with agonist and antagonist ligands  in vitro  (37, 
38). Altogether, these results raise the intriguing possibility 
that the interaction between CDl-expressing cortical thymo- 
cytes and Vet 14-Jo~281 TCR-expressing thymocytes activates 
a distinct signaling pathway that induces downmodulation 
of CD8  as well as induction  of NK receptors, particularly 
those that may dampen TC1K-mediated signaling (39),  thus 
allowing cells to escape negative selection. 
An important property of CD4 NK1 T  cells, that of rap- 
idly releasing IL-4 on TC1K engagement, is also conferred 
to  transgenic  CD4  cells,  resulting  in  the  secretion  of a 
markedly biased Th2  cytokine profile upon primary poly- 
clonal stimulation in vitro and in vivo. The increased base- 
line  levels  of IgG1  and  IgE  Ig  isotypes  in  Vod4-Jot281 
transgenic mice therefore further indicate that NK1 T  cells 
play a physiological role in regulating the Thl  vs Th2 dif- 
ferentiation of immune responses. 
On the other hand, it is also remarkable that, in the face 
of a prodigious increase in potentially available IL-4 at the 
outset of immune responses, Vel14-J0~281  transgenics con- 
serve normal levels of other isotypes, in particular the Thl- 
controlled lgG2a. This finding suggests that there exist im- 
mune responses, presumably those  in which  CD1  is not 
induced, where NK1 T cells are simply not recruited, or per- 
haps even in which  they are inactivated by IL-12, as was 
recently  documented  in  Listeria monocytogenes infection 
(40).  Indeed, preliminary experiments have shown that im- 
munization ofVell4-Jo~281 transgenic mice with KLH and 
RIBI adjuvant  (which  includes  mycolic acid  and lipid A) 
induces antigen-specific T  ceils that produce IL-4 and IFN-~/ 
in  amounts similar to  those  of normal mice  (not shown). 
We also found that Vod4-Jo~281  B6 transgenics recovered 
from Leishmania major infection with virtually the same ki- 
netics as nontransgenic littermates  (Scott, P.,  and A. Ben- 
delac, unpublished results). 
Although the range of conditions in which NK1 T  cells 
are recruited to drive the differentiation of helper cells re- 
mains to be determined, the fact that NK1  T  cells  are au- 
toreactive to CD1 and that they have been shown to medi- 
ate Th2 help for B  cells upon anti-IgD injection,  suggests 
that they may specialize in providing rapid help in a non- 
antigen-specific way. The induction of CD1, for example, 
may serve as a clue that triggers NK1 T  cells, bypassing the 
need  for  associative  recognition  of antigen  by  classic  T 
helper cells, thus providing a jump start for the effector re- 
sponse.  Future  challenges  will be to  elucidate  the  precise 
cellular and molecular pathways that drive the differentia- 
tion ofNK1 T  cells in the thymus, and their recruitment in 
the course of immune responses. 
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